Global News and Digital Insights
for the Healthcare Industry

GSK bags FDA’s nod for Priorix, a vaccine for measles

With measles making a comeback after the pandemic, Priorix, a vaccine on the market for over 25 years, is approved by the FDA for the protection of kids of age 1 or older against measles, mumps, and rubella (MMR). During the pandemic, the immunisation schedules were disrupted, that rendered the measles outbreak among children. Priorix was first available in Germany and other countries of Europe. However, now it has been approved in the US as well, in competition with Merck’s M-M-R II vaccine. With two doses of the vaccine, the children can be protected against the new outbreak.

Read More from FiercePharma

Share on facebook
Share on twitter
Share on linkedin